Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D09QCB
|
|||
Drug Name |
PMID29334795-Compound-56
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
TAKEDA PHARMACEUTICAL COMPANY LIMITED RUPRAH, Parminder, Kaur MERCHANT, Kevin, John WALSH, Louise, Marie KERR, Catrina, Morven FIELDHOUSE, Charlotte HARRISSON, David MAINE, Stephanie HAZEL, Katherine
|
|||
Structure |
Download2D MOL |
|||
Formula |
C23H33NO2
|
|||
Canonical SMILES |
COC1CCC(CC1)(C2=CC=C(C=C2)C=C3CCN(CC3)C4CCC4)O
|
|||
InChI |
1S/C23H33NO2/c1-26-22-9-13-23(25,14-10-22)20-7-5-18(6-8-20)17-19-11-15-24(16-12-19)21-3-2-4-21/h5-8,17,21-22,25H,2-4,9-16H2,1H3
|
|||
InChIKey |
PTJSNMGOBXREIH-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Histamine H3 receptor (H3R) | Target Info | . | [1] |
Target's Patent Info | Histamine H3 receptor (H3R) | Target's Patent Info | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Reactome | Histamine receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | Monoamine Transport | |||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.